University of Arizona - Center for Sleep, Circadian, and Neuroscience Research
Tucson, Arizona, 85724, United States
Location status: Recruiting
NCT Number: NCT07438912
This study examines whether wakefulness during the biological night (2:00-4:00 AM) is associated with increased negative mood, impaired decision-making, and suicidal thoughts. Adults with a history of suicidal ideation in the past six months will complete laboratory and home-based assessments under varying levels of sleep pressure. Participants will be evaluated during late-night wakefulness and under conditions of both higher and lower sleep pressure. The goal of the study is to better understand the biological and behavioral mechanisms that may contribute to elevated suicide risk during nocturnal wakefulness.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Not applicable
Tucson, Arizona, 85724, United States
Location status: Recruiting
Suicide risk is elevated during the biological night, particularly between 2:00 and 4:00 AM. Observational and epidemiologic data suggest that nocturnal wakefulness is associated with increased negative affect, impaired decision-making, and greater suicidal ideation. The "Mind After Midnight" hypothesis proposes that wakefulness during the biological night exposes individuals to a combination of circadian vulnerability and homeostatic sleep pressure that contributes to emotional and cognitive dysregulation.
This study will recruit approximately 90 adults with a history of suicidal ideation in the past six months. Participants will complete both home-based and laboratory-based procedures. Laboratory assessments will evaluate mood, hopelessness, suicidal ideation, impulsivity, and decision-making at different times of day, including 2:00-4:00 AM. To examine the role of homeostatic sleep pressure, participants will complete late-night assessments under two conditions: (1) high sleep pressure (remaining awake until 2:00 AM) and (2) low sleep pressure (sleeping and being awakened at 2:00 AM). Circadian factors will be assessed using behavioral measures and physiologic markers, including melatonin.
The goal of the study is to experimentally test whether nocturnal wakefulness contributes to suicide-associated cognitive and affective processes and to identify underlying chronobiological mechanisms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants undergo an experimental manipulation of homeostatic sleep pressure involving controlled wakefulness or scheduled awakening during the biological night. Mood, suicidal ideation, impulsivity, and decision-making are assessed during overnight laboratory sessions.
Time frame: Visit 1(day 2, night 2), Visit 2 (day 2, night 2)
Total score on the BECK Hopelessness scale (BHS)
Time frame: Visit 1(day 2, night 2), Visit 2 (day 2, night 2)
BART total score
Time frame: Visit 1(day 2, night 2), Visit 2 (day 2, night 2)
PANAS negative affect score
Contact information is provided by the study sponsor or research team.
Darilyn Rivera-Collazo, MS
CONTACT
Denisse Armenta
CONTACT
University of Arizona
Other
The Mind After Midnight: Mechanistic Examination of Nocturnal Wakefulness as a Suicide Risk Factor
Acronym: MaM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06921226
Behavior, Behavioral Symptoms
Chambéry, Savoie, France
View Trial DetailsNCT05647044
Behavior, Behavioral Symptoms
Hines, Illinois, United States
View Trial DetailsNCT03679962
Behavior, Behavioral Symptoms
Billings, Montana, United States
View Trial DetailsNCT02248675
Anxiety Disorders, Behavior
Syracuse, New York, United States
View Trial Details